miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk
Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers · 2024
Read miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk by Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11611913.txt.
Description
Xia Wang and co-authors trace how a hormone-blocking drug may lower ovarian cancer risk in women at high inherited risk. The drug, flutamide, blocks male hormone signals, a pathway now tied to this cancer's start. Their 2024 study began with tissue from high-risk women, some treated with the drug and some not, plus tissue from low-risk women for comparison.
Drug treatment brought the tissues' small RNA profile back toward the low-risk pattern, lifting a family called miR-449. In lab cells, the drug raised those same RNAs, and adding copies of them cut levels of two proteins that drive the cancer: the hormone receptor itself and a growth signal receiver. Cancer cells also moved less. The authors say the drug fights the pathway twice over, and may suit prevention for women with low miR-449.
Catalog record
| CREATOR | Xia Wang, Ho-Hyung Woo, Michelle Wei, Steven Gibson, Mitzi Miranda, Demaretta Rush, Janiel Cragun, Wenxin Zheng, Guang Yao, Setsuko K Chambers |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |